Innovent Biologics (IVBXF) announced that the first participant has been successfully dosed in a Phase 3 clinical trial, GLORY-OSA, of mazdutide, a dual glucagon and glucagon-like peptide-1 receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea and obesity. This is the seventh Phase 3 clinical study of mazdutide in China, continuing to explore its potential in managing obesity and a range of metabolic syndromes, with the aim of generating more comprehensive and high-quality evidence to support clinical application.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVBXF:
- Innovent Biologics’ New Drug Application for Advanced Renal Cell Carcinoma Accepted in China
- Innovent Biologics Announces Annual General Meeting and Key Resolutions
- Innovent Biologics Reports Over 40% Revenue Growth in Q1 2025
- Innovent Biologics’ Limertinib Gains Approval for First-Line Lung Cancer Treatment